This trial is testing Tildacerfont to see if it can help adults with classic CAH reduce their steroid doses. The study will initially compare Tildacerfont to another treatment for several months, then allow all participants to use Tildacerfont for an extended period, with an optional longer-term extension. The goal is to find a safer way to manage CAH by lowering the need for high steroid doses. Tildacerfont has been studied in earlier trials for adults with classic congenital adrenal hyperplasia (CAH).
This trial is testing a medication called tildacerfont to see if it is safe and effective for people with Congenital Adrenal Hyperplasia (CAH). The treatment involves taking the medication for a period of time, followed by a safety check. Tildacerfont aims to help balance hormones that are not properly regulated in people with CAH. Tildacerfont has been studied for its effectiveness in adults with Congenital Adrenal Hyperplasia.
This trial is testing a new drug called CRN04894 in people with a genetic condition called classic congenital adrenal hyperplasia (CAH). The condition affects hormone production, and current treatments may not work well. The study will see if CRN04894 can safely and effectively help manage hormone levels by targeting the underlying cause of CAH.